文献速递临床试验与 GCP流行病学与生物统计

晚期早产产前皮质类固醇后的神经发育结局:ALPS随访研究

Neurodevelopmental Outcomes After Late Preterm Antenatal Corticosteroids: The ALPS Follow-Up Study.
PubMed 文献 · JAMA · 2024-01-01

ALPS试验发现34至36周产前倍他米松可减少新生儿短期呼吸系统疾病,但增加新生儿低血糖风险。本前瞻性随访研究纳入949名完成DAS-II评估的6岁及以上儿童,发现倍他米松组与安慰剂组的一般概念能力评分低于85的比例无差异(17.1% vs 18.5%,校正相对风险0.94,95%CI 0.73-1.22),次要结局亦无差异。

要点

  • 产前倍他米松组与安慰剂组的一般概念能力评分低于85的比例无差异。
  • 校正相对风险0.94(95%CI 0.73-1.22),未达统计学显著。
  • 次要结局及敏感性分析均未观察到组间差异。

核心结论

  • 对有晚期早产分娩风险者给予产前皮质类固醇,虽增加新生儿低血糖发生率,但与6岁及以上儿童不良神经发育结局无关。

研究设计与样本

  • 前瞻性随访研究,纳入2011至2016年参与母胎医学单位网络周期的13个中心的多中心随机临床试验中分娩父母所生的6岁及以上儿童,随访时间为2017至2022年。
  • 2831名儿童中1026名入组,949名(倍他米松组479名,安慰剂组470名)在中位年龄7岁(IQR 6.6-7.6岁)完成DAS-II评估。
  • 暴露为12毫克倍他米松肌肉注射,间隔24小时给药两次。

主要发现

  • 主要结局一般概念能力评分低于85发生于倍他米松组82名(17.1%)与安慰剂组87名(18.5%),校正相对风险0.94(95%CI 0.73-1.22)。
  • 次要结局包括粗大运动功能分类系统级别、社交反应量表和儿童行为量表评分,均未观察到差异。
  • 使用逆概率加权或对失访儿童赋值结局的敏感性分析也未发现组间差异。
  • 除新生儿低血糖在倍他米松组更常见外,两组母婴及儿童特征相似。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The Antenatal Late Preterm Steroids (ALPS) trial changed clinical practice in the United States by finding that antenatal betamethasone at 34 to 36 weeks decreased short-term neonatal respiratory morbidity. However, the trial also found increased risk of neonatal hypoglycemia after betamethasone. This follow-up study focused on long-term neurodevelopmental outcomes after late preterm steroids. OBJECTIVE: To evaluate whether administration of late preterm (34-36 completed weeks) corticosteroids affected childhood neurodevelopmental outcomes. DESIGN, SETTING, AND PARTICIPANTS: Prospective follow-up study of children aged 6 years or older whose birthing parent had enrolled in the multicenter randomized clinical trial, conducted at 13 centers that participated in the Maternal-Fetal Medicine Units (MFMU) Network cycle from 2011-2016. Follow-up was from 2017-2022. EXPOSURE: Twelve milligrams of intramuscular betamethasone administered twice 24 hours apart. MAIN OUTCOME AND MEASURES: The primary outcome of this follow-up study was a General Conceptual Ability score less than 85 (-1 SD) on the Differential Ability Scales, 2nd Edition (DAS-II). Secondary outcomes included the Gross Motor Function Classification System level and Social Responsiveness Scale and Child Behavior Checklist scores. Multivariable analyses adjusted for prespecified variables known to be associated with the primary outcome. Sensitivity analyses used inverse probability weighting and also modeled the outcome for those lost to follow-up. RESULTS: Of 2831 children, 1026 enrolled and 949 (479 betamethasone, 470 placebo) completed the DAS-II at a median age of 7 years (IQR, 6.6-7.6 years). Maternal, neonatal, and childhood characteristics were similar between groups except that neonatal hypoglycemia was more common in the betamethasone group. There were no differences in the primary outcome, a general conceptual ability score less than 85, which occurred in 82 (17.1%) of the betamethasone vs 87 (18.5%) of the placebo group (adjusted relative risk, 0.94; 95% CI, 0.73-1.22). No differences in secondary outcomes were observed. Sensitivity analyses using inverse probability weighting or assigning outcomes to children lost to follow-up also found no differences between groups. CONCLUSION AND RELEVANCE: In this follow-up study of a randomized clinical trial, administration of antenatal corticosteroids to persons at risk of late preterm delivery, originally shown to improve short-term neonatal respiratory outcomes but with an increased rate of hypoglycemia, was not associated with adverse childhood neurodevelopmental outcomes at age 6 years or older.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Gyamfi-Bannerman C, Clifton RG, Tita ATN, et al. Neurodevelopmental Outcomes After Late Preterm Antenatal Corticosteroids: The ALPS Follow-Up Study. JAMA. 2024. PMID: 38656759. doi:10.1001/jama.2024.4303

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。